Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans.

Many experimental protocols and published guidelines for performing bronchoscopy, bronchoalveolar lavage (BAL), bronchial biopsies, and segmental antigen challenge (SAC) of allergic asthmatic subjects recommend treating subjects with a beta-agonist prior to the procedure. However, the effect of beta-agonist pretreatment has not been reported. In a retrospective analysis of ragweed allergic subjects undergoing bronchoscopy, SAC, and BAL, we examined the effect of albuterol pretreatment on cellular influx and lung injury produced by antigen challenge. Forty-eight subjects, 17 who received no pretreatment and 31 who received four puffs of albuterol prior to bronchoscopy, comprised the study groups. No parameter monitored in BAL fluid 24 h after SAC (total cells, macrophages, neutrophils, eosinophils, lymphocytes, total protein, albumin, or eosinophil cationic protein) differed in subjects pretreated with albuterol when compared with subjects who were not pretreated. Although additional, prospective studies are warranted, we conclude that beta-agonist pretreatment of experimental subjects does not alter many aspects of the inflammatory response produced by SAC.

[1]  J. Murray,et al.  A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. , 1996, The Journal of allergy and clinical immunology.

[2]  S. Peters,et al.  Pulmonary inflammation after segmental ragweed challenge in allergic asthmatic and nonasthmatic subjects. , 1995, American journal of respiratory and critical care medicine.

[3]  D. McDonald,et al.  The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. , 1994, The American journal of physiology.

[4]  D. Smith,et al.  Bronchoalveolar lavage in asthma. An update and perspective. , 1993, The American review of respiratory disease.

[5]  S. Peters,et al.  Immunoglobulin E-mediated increase in vascular permeability correlates with eosinophilic inflammation. , 1993, The American review of respiratory disease.

[6]  S. Peters,et al.  Effect of antigen dose on the recruitment of inflammatory cells to the lung by segmental antigen challenge. , 1992, The Journal of allergy and clinical immunology.

[7]  N. Choudry,et al.  A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. , 1992, The Journal of allergy and clinical immunology.

[8]  W. Busse,et al.  Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. , 1991, The American review of respiratory disease.

[9]  D. Broide,et al.  Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. , 1991, The Journal of allergy and clinical immunology.

[10]  J. Bousquet,et al.  Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. , 1991, The Journal of allergy and clinical immunology.

[11]  E. Bleecker,et al.  Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. , 1991, The American review of respiratory disease.

[12]  E. Bleecker,et al.  Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. , 1990, The American review of respiratory disease.

[13]  K. Chung,et al.  Beta2-Adrenergic Receptors on Eosinophils: Binding and Functional Studies , 1990 .

[14]  S. Liggett.  Identification and Characterization of a Homogeneous Population of β2-Adrenergic Receptors on Human Alveolar Macrophages , 1989 .

[15]  S. Wenzel,et al.  Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. , 1988, The American review of respiratory disease.

[16]  G. Hunninghake,et al.  Bronchoalveolar lavage of allergic asthmatic patients following allergen bronchoprovocation. , 1986, Chest.

[17]  P. Howarth,et al.  Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. , 2015, The American review of respiratory disease.

[18]  Workshopcommittee.  Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in individuals with asthma*1, *2, *3, *4 , 1985 .

[19]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[20]  S. Titinchi,et al.  Circadian variation in number and affinity of beta 2-adrenoceptors in lymphocytes of asthmatic patients. , 1984, Clinical science.

[21]  S. Peters,et al.  Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. , 1982, The American review of respiratory disease.

[22]  L. Lichtenstein,et al.  The role of agonists that activate adenylate cyclase in the control of cAMP metabolism and enzyme release by human polymorphonuclear leukocytes. , 1980, Journal of immunology.

[23]  H. Bourne,et al.  Modulation of Inflammation and Immunity by Cyclic AMP , 1974 .